Synthetic cathinone adulteration of illegal drugs - PubMed (original) (raw)
Review
Synthetic cathinone adulteration of illegal drugs
Chicora F Oliver et al. Psychopharmacology (Berl). 2019 Mar.
Abstract
Rationale: Current prevalence estimates of synthetic cathinone ("bath salt") use may be underestimates given that traditional metrics (e.g., surveys, urinalysis) often fail to capture the emergent issue of synthetic cathinone adulteration of more common illegal drugs, such as ecstasy (3,4-methylenedioxymethamphetamine).
Objectives: This review examines the evolution of synthetic cathinones and prevalence of use over the past decade in the United States. We also review methods of self-report and biological testing of these compounds as well as adverse outcomes associated with adulterated drug use.
Results: Synthetic cathinone use emerged in the United States by 2009 with use associated with tens of thousands of poisonings. Reported poisonings and self-reported use have substantially decreased over the past five years. However, our review suggests that current estimates of use are underestimates due to underreporting stemming primarily from unknown or unintentional use of adulterated formulations of relatively popular illegal drugs, such as ecstasy.
Conclusions: While intentional synthetic cathinone use has decreased in recent years, evidence suggests that prevalence of use is underestimated. Testing of drugs and/or biological specimens can improve the accuracy of synthetic cathinone use estimates. Furthermore, we advocate that researchers and clinicians should become better aware that exposure to these potent compounds (e.g., as adulterants) often occurs unknowingly or unintentionally. To improve our understanding of synthetic cathinone adulteration, research utilizing a combinatorial approach (survey and biological testing) will help more accurately estimate the prevalence and impact of this public health issue.
Keywords: Addiction; Adulteration; Ecstasy; Novel psychoactive substances; Synthetic cathinones.
Conflict of interest statement
Conflicts of Interest: There are no conflicts of interest to report.
Similar articles
- The health threat of new synthetic opioids as adulterants of classic drugs of abuse.
Rinaldi R, Negro F, Minutillo A. Rinaldi R, et al. Clin Ter. 2020 Mar-Apr;171(2):e107-e109. doi: 10.7417/CT.2020.2198. Clin Ter. 2020. PMID: 32141480 - Hair testing to assess both known and unknown use of drugs amongst ecstasy users in the electronic dance music scene.
Palamar JJ, Salomone A, Gerace E, Di Corcia D, Vincenti M, Cleland CM. Palamar JJ, et al. Int J Drug Policy. 2017 Oct;48:91-98. doi: 10.1016/j.drugpo.2017.07.010. Epub 2017 Aug 12. Int J Drug Policy. 2017. PMID: 28810159 Free PMC article. - Shifts in Unintentional Exposure to Drugs Among People Who Use Ecstasy in the Electronic Dance Music Scene, 2016-2019.
Palamar JJ, Salomone A. Palamar JJ, et al. Am J Addict. 2021 Jan;30(1):49-54. doi: 10.1111/ajad.13086. Epub 2020 Jul 28. Am J Addict. 2021. PMID: 32813326 Free PMC article. - Synthetic cathinones - From natural plant stimulant to new drug of abuse.
Pieprzyca E, Skowronek R, Nižnanský Ľ, Czekaj P. Pieprzyca E, et al. Eur J Pharmacol. 2020 May 15;875:173012. doi: 10.1016/j.ejphar.2020.173012. Epub 2020 Feb 19. Eur J Pharmacol. 2020. PMID: 32087255 Review. - Synthetic cathinones: a new public health problem.
Karila L, Megarbane B, Cottencin O, Lejoyeux M. Karila L, et al. Curr Neuropharmacol. 2015 Jan;13(1):12-20. doi: 10.2174/1570159X13666141210224137. Curr Neuropharmacol. 2015. PMID: 26074740 Free PMC article. Review.
Cited by
- Comparison of Psychiatric and Clinical Profiles Between People Who Use Synthetic Cathinones and Methamphetamine: A Matched Case-Control Study.
Lin CH, Chen JJ, Chan CH. Lin CH, et al. J Clin Psychopharmacol. 2023 Mar-Apr 01;43(2):122-130. doi: 10.1097/JCP.0000000000001649. Epub 2023 Jan 28. J Clin Psychopharmacol. 2023. PMID: 36706307 Free PMC article. - Increasing Willingness to Use Synthetic Drugs if Offered among Electronic Dance Music Party Attendees, 2017-2019.
Palamar JJ. Palamar JJ. J Psychoactive Drugs. 2020 Sep-Oct;52(4):324-333. doi: 10.1080/02791072.2020.1761574. Epub 2020 May 19. J Psychoactive Drugs. 2020. PMID: 32429796 Free PMC article. - Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones.
Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, Baumann MH, Fantegrossi WE. Fitzgerald LR, et al. Neuropharmacology. 2024 Mar 1;245:109827. doi: 10.1016/j.neuropharm.2023.109827. Epub 2023 Dec 27. Neuropharmacology. 2024. PMID: 38154512 - Interpol Review of Drug Analysis 2019-2022.
Love D, Jones NS. Love D, et al. Forensic Sci Int Synerg. 2023 Jan 5;6:100299. doi: 10.1016/j.fsisyn.2022.100299. eCollection 2023. Forensic Sci Int Synerg. 2023. PMID: 36655023 Free PMC article. Review. No abstract available. - The influence of viewing a headline about ecstasy/Molly adulteration on future intentions to use.
Palamar JJ, Acosta P, Cleland CM. Palamar JJ, et al. J Subst Use. 2020;25(1):95-100. doi: 10.1080/14659891.2019.1664660. Epub 2019 Sep 12. J Subst Use. 2020. PMID: 33122965 Free PMC article.
References
- Alles GA, Fairchild MD, Jensen M (1961) Chemical pharmacology of Catha edulis. J Med Pharm Chem 3:323–52 - PubMed
- Anneken JH, Angoa-Pérez M, Kuhn DM (2015) 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter. J Neurochem 133:211–222. doi: 10.1111/jnc.13048 - DOI - PMC - PubMed
- American Association of Poison Control Centers 2016. Bath salts data. https://aapcc.s3.amazonaws.com/files/library/Bath_Salts_Web_Data_through... Accessed on 30 November 2018
Publication types
MeSH terms
Substances
Grants and funding
- T32NS007413/National Institute of Neurological Disorders and Stroke
- F99NS105218/National Institute of Neurological Disorders and Stroke
- K01 DA038800/DA/NIDA NIH HHS/United States
- P30 DA013429/DA/NIDA NIH HHS/United States
- K01DA038800/National Institute on Drug Abuse
- T32 NS007413/NS/NINDS NIH HHS/United States
- F99 NS105218/NS/NINDS NIH HHS/United States
- T32 DA007237/DA/NIDA NIH HHS/United States
- R01 DA039139/DA/NIDA NIH HHS/United States
- R01 DA039139/National Institute on Drug Abuse
- T32DA007237/National Institute on Drug Abuse
LinkOut - more resources
Full Text Sources
Miscellaneous